Aurora BioPharma, Inc. to Present at the Landmark Venture Forum at the Palm Beach Marriott Resort & Spa – Singer Island
CAMBRIDGE, MA - December 15, 2015 - Aurora BioPharma, Inc., a private immune-oncology company developing CAR T therapy, checkpoint inhibitors for solid tumors, announces its CEO, Robert Brooks, will present at the Landmark Venture Forum at the Palm Beach Marriott Resort & Spa – Singer Island on December 15, 2015. This investor, by-invitation only, event will feature presentations from select companies seeking investments.
About Landmark Angels
Landmark Angels invests in opportunities ranging from $100K to $2M with the ability to syndicate with other angel and venture capital groups. Companies are selected from industry contacts and conferences, leading education institutions, and direct applications. Landmark Angels provides entrepreneurs with the capital, invaluable advice, and key industry contacts to succeed in an ever evolving environment where new technologies are developed at a demanding pace.
About Aurora BioPharma, Inc.
Aurora is a biotechnology company based in Cambridge, Massachusetts commercializing cutting-edge cancer immunotherapy drugs in FDA human clinical trials. Aurora's portfolio includes Chimeric Antigen Receptor T-cell therapy (CAR T), vaccines and checkpoint inhibitor combinations. Aurora's team is comprised of experienced leading research scientists and business professionals with successful track records in the industry.
Glioblastoma is an incurable lethal brain cancer that kills 45,000 people annually in the US and Europe, most well-known has been Senator Ted Kennedy and Vice President Joe Biden’s son. Current Standard of Care consists of surgery, radiation and chemotherapy, with about one year survival. Temozolomide was FDA approved on only a nominal 10 more weeks of survival, or a median survival of 15 months. A Phase I clinical trial with Aurora’s CAR T therapy AU-105 was conducted with 16 Glioblastoma Brain cancer patients, and showed it was well tolerated, no severe adverse events, with strong signs of efficacy, nearly double median survival versus historic median survival. Aurora plans to apply to the FDA for Breakthrough and Orphan Status, as well as plan a randomized multi-site, multi-country Phase II trial of Early Diagnosed Glioblastoma with an endpoint of Overall Survival, and milestone of achieving Fast-Track Drug Approval. Aurora has just started to fund the world’s first Phase I/II intracranial direct injection CAR T trial for refractory recurrent Glioblastoma patients, whose historic median survival is only 32 weeks.
Osteosarcoma is a bone cancer that affects mostly children and adolescents, with poor survival even after amputation of limbs and chemotherapy. A Phase I CAR T trial with AU-105 in 19 Sarcoma (16 Osteosarcoma) patients was completed showing safety with strong signals of efficacy, with 90% of a Partial Response patient’s tumor necrotic, and a patient child alive for three years. A Phase II trial is being planned in combination with PD-1 antibody from a major drug company. Aurora intends in the future to plan a CAR T trial in breast and gastric cancer.
Aurora has an equity interest in MedVax Technologies, Inc. that is developing a P53 Dendritic Cell Vaccine, MX-225, that has completed a Phase IIa trial in 54 patients with Small Cell Lung Cancer. A planned Phase I/II trial with MX-225 and a combination of PD-1 from a major drug company is planned in lung cancer, and a Phase II trial is ongoing with MX-225 and Indoximod, an IDO inhibitor drug from NewLink Genetics, in partnership with Roche Holding AG.
For more information, please visit www.aurorabiopharma.net
This press release and any statements of representatives and partners of Aurora BioPharma, Inc. (the “Company”) related thereto contain, or may contain, among other things, certain “forward-looking statements” within the meaning of the U.S. federal securities laws. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company’s plans, objectives, projections, expectations, and intentions, and other statements identified by words such as “projects,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” or similar expressions. These statements are based upon the current beliefs and expectations of the Company’s management. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors, many of which are beyond the Company’s control. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
For media inquiries, please contact:
VP, Business Development & Public Relations
Aurora BioPharma, Inc.
Harvard Square, One Mifflin Place, Suite 400
Cambridge, MA 02138
Tel: 617-674-7718 - Fax: 617-674-7701
Ingraham Building, 25 SE 2nd Avenue, Suite 504
Miami, FL 33131
Tel: 305-371-2301 - Fax: 305-371-2301
email@example.com - www.aurorabiopharma.net
- New Paradigm in Cancer Immunotherapy -
Source: Aurora BioPharma, Inc.